Could a cheaper copy of a key chemo drug work just as well?
NCT ID NCT07648940
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new formulation of the chemotherapy drug doxorubicin (Doxopeg) to the standard version (Caelyx) in people with advanced ovarian cancer or metastatic breast cancer. The goal is to see if the two drugs are absorbed and processed by the body in the same way. Participants receive a single dose of each drug in a random order, and blood samples are taken over two weeks to measure drug levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pegylated liposomal doxorubicin (Doxopeg, Caelyx)
What this could lead to
If the new formulation is shown to be equivalent, it could offer a more affordable or accessible treatment option for advanced ovarian and breast cancers.
What could go wrong
This is an early-phase bioequivalence study, not a test of effectiveness. The new drug may not match the reference drug in real-world use, and side effects like heart damage or hand-foot syndrome remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adium S.A.
São Paulo, Brazil